Molecular mechanisms regulating impaired neurogenesis of Fragile X syndrome human embryonic stem cells

Stem Cells and Development

Volumn 24, Issue 20, 2015, Pages 2353-2365

  Telias, Michael ^a,b   Mayshar, Yoav ^a   Amit, Ami ^a   Ben Yosef, Dalit ^a,b  

^a LIS MATERNITY HOSPITAL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; TRANSCRIPTION FACTOR SOX; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX9; FMR1 PROTEIN, HUMAN; FMR1 PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, HUMAN; GSK3B PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; FRAGILE X SYNDROME; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; HUMAN EMBRYONIC STEM CELL; METABOLISM; NERVE CELL; PATHOLOGY;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMAN EMBRYONIC STEM CELLS; HUMANS; NEUROGENESIS; NEURONS;

EID: 84943526479     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2015.0220     Document Type: Article

References (66)

1. Penagarikano O, JG Mulle and ST Warren. (2007). The pathophysiology of fragile X syndrome. Annu Rev Genomics Hum Genet 8:109-129.
2. Verkerk AJ, M Pieretti, JS Sutcliffe, YH Fu, DP Kuhl, A Pizzuti, O Reiner, S Richards, MF Victoria, FP Zhang, et al. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905-914.
3. Willemsen R, CJ Bontekoe, LA Severijnen and BA Oostra. (2002). Timing of the absence of FMR1 expression in full mutation chorionic villi. Hum Genet 110:601-605.
4. Li Y and X Zhao. (2014). Fragile X proteins in stem cell maintenance and differentiation. Stem Cells 32:1724-1733.
5. Wan L, TC Dockendorff, TA Jongens and G Dreyfuss. (2000). Characterization of dFMR1, a Drosophila melanogaster homolog of the fragile X mental retardation protein. Mol Cell Biol 20:8536-8547.
6. den Broeder MJ, H van der Linde, JR Brouwer, BA Oostra, R Willemsen and RF Ketting. (2009). Generation and characterization of FMR1 knockout zebrafish. PLoS One 4:e7910.
7. Mientjes EJ, I Nieuwenhuizen, L Kirkpatrick, T Zu, M Hoogeveen-Westerveld, L Severijnen, M Rife, R Willemsen, DL Nelson and BA Oostra. (2006). The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol Dis 21:549-555.
8. Irwin SA, B Patel, M Idupulapati, JB Harris, RA Crisostomo, BP Larsen, F Kooy, PJ Willems, P Cras, et al. (2001). Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet 98:161-167.
9. Schwartz PH, F Tassone, CM Greco, HE Nethercott, B Ziaeian, RJ Hagerman and PJ Hagerman. (2005). Neural progenitor cells from an adult patient with fragile X syndrome. BMC Med Genet 6:2.
10. Bhattacharyya A, E McMillan, K Wallace, TC Tubon, Jr., EE Capowski and CN Svendsen. (2008). Normal neurogenesis but abnormal gene expression in human fragile X cortical progenitor cells. Stem Cells Dev 17:107-117.
11. Castren M, T Tervonen, V Karkkainen, S Heinonen, E Castren, K Larsson, CE Bakker, BA Oostra and K Akerman. (2005). Altered differentiation of neural stem cells in fragile X syndrome. Proc Natl Acad Sci U S A 102:17834-17839.
12. Castren M. (2006). Differentiation of neuronal cells in fragile X syndrome. Cell Cycle 5:1528-1530.
13. Braun K and M Segal. (2000). FMRP involvement in formation of synapses among cultured hippocampal neurons. Cereb Cortex 10:1045-1052.
14. Thomson JA, J Itskovitz-Eldor, SS Shapiro, MA Waknitz, JJ Swiergiel, VS Marshall and JM Jones. (1998). Em-bryonic stem cell lines derived from human blastocysts. Science 282:1145-1147.
15. Telias M and D Ben-Yosef. (2014). Modeling neurodevelopmental disorders using human pluripotent stem cells. Stem Cell Rev 10:494-511.
16. Eiges R, A Urbach, M Malcov, T Frumkin, T Schwartz, A Amit, Y Yaron, A Eden, O Yanuka, N Benvenisty and D Ben-Yosef. (2007). Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 1:568-577.
17. Telias M, M Segal and D Ben-Yosef. (2013). Neural differentiation of fragile X human embryonic stem cells reveals abnormal patterns of development despite successful neurogenesis. Dev Biol 374:32-45.
18. Sheridan SD, KM Theriault, SA Reis, F Zhou, JM Madison, L Daheron, JF Loring and SJ Haggarty. (2011). Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile x syndrome. PLoS One 6:e26203.
19. Halevy T, C Czech and N Benvenisty. (2014). Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem cells. Stem Cell Reports 4:37-46.
20. Kiefer JC. (2007). Back to basics: Sox genes. Dev Dyn 236:2356-2366.
21. Wegner M and CC Stolt. (2005). From stem cells to neurons and glia: a Soxist's view of neural development. Trends Neurosci 28:583-588.
22. Malas S, M Postlethwaite, A Ekonomou, B Whalley, S Nishiguchi, H Wood, B Meldrum, A Constanti and V Episkopou. (2003). Sox1-deficient mice suffer from epilepsy associated with abnormal ventral forebrain development and olfactory cortex hyperexcitability. Neuroscience 119:421-432.
23. Laumonnier F, N Ronce, BC Hamel, P Thomas, J Lespinasse, M Raynaud, C Paringaux, H Van Bokhoven, V Kalscheuer, et al. (2002). Transcription factor SOX3 is involved in X-linked mental retardation with growth hormone deficiency. Am J Hum Genet 71:1450-1455.
24. Hamel BC, AP Smits, BJ Otten, B van den Helm, HH Ropers and EC Mariman. (1996). Familial X-linked mental retardation and isolated growth hormone deficiency: clinical and molecular findings. Am J Med Genet 64:35-41.
25. Lee YH and JP Saint-Jeannet. (2011). Sox9 function in craniofacial development and disease. Genesis 49:200-208.
26. Portis S, B Giunta, D Obregon and J Tan. (2012). The role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndrome. Int J Physiol Pathophysiol Pharmacol 4:140-148.
27. Guo W, AC Murthy, L Zhang, EB Johnson, EG Schaller, AM Allan and X Zhao. (2011). Inhibition of GSK3 beta improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum Mol Genet 1:681-691.
28. Luo Y, G Shan, W Guo, RD Smrt, EB Johnson, X Li, RL Pfeiffer, KE Szulwach, R Duan, et al. (2010). Fragile x mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet 6:e1000898.
29. Kuwabara T, J Hsieh, A Muotri, G Yeo, M Warashina, DC Lie, L Moore, K Nakashima, M Asashima and FH Gage. (2009). Wnt-mediated activation of NeuroD1 and retroelements during adult neurogenesis. Nat Neurosci 12:1097-1105.
30. Frumkin T, M Malcov, M Telias, V Gold, T Schwartz, F Azem, A Amit, Y Yaron and D Ben-Yosef. (2010). Human embryonic stem cells carrying mutations for severe genetic disorders. In Vitro Cell Dev Biol Anim 46:327-336.
31. Telias M, M Segal and D Ben-Yosef. (2014). Electrical maturation of neurons derived from human embryonic stem cells. F1000Res 3:196.
32. Zhang SC, M Wernig, ID Duncan, O Brustle and JA Thomson. (2001). In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 19:1129-1133.
33. Hicks AU, RS Lappalainen, S Narkilahti, R Suuronen, D Corbett, J Sivenius, O Hovatta and J Jolkkonen. (2009). Transplantation of human embryonic stem cell-derived neural precursor cells and enriched environment after cortical stroke in rats: cell survival and functional recovery. Eur J Neurosci 29:562-574.
34. Banda E and L Grabel. (2015). Directed differentiation of human embryonic stem cells into neural progenitors. Methods Mol Biol 1307:289-298.
35. Elkabetz Y and L Studer. (2008). Human ESC-derived neural rosettes and neural stem cell progression. Cold Spring Harb Symp Quant Biol 73:377-387.
36. Elkabetz Y, G Panagiotakos, G Al Shamy, ND Socci, V Tabar and L Studer. (2008). Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev 22:152-165.
37. Doers ME, MT Musser, R Nichol, ER Berndt, M Baker, TM Gomez, SC Zhang, L Abbeduto and A Bhattacharyya. (2014). iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth. Stem Cells Dev 23:1777-1787.
38. Halevy T, C Czech and N Benvenisty. (2015). Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem cells. Stem Cell Reports 4:37-46.
39. Castren ML and E Castren. (2014). BDNF in fragile X syndrome. Neuropharmacology 76 Pt C:729-736.
40. Erickson JT, TA Brosenitsch and DM Katz. (2001). Brainderived neurotrophic factor and glial cell line-derived neurotrophic factor are required simultaneously for survival of dopaminergic primary sensory neurons in vivo. J Neurosci 21:581-589.
41. Miyagi S, H Kato and A Okuda. (2009). Role of SoxB1 transcription factors in development. Cell Mol Life Sci 66:3675-3684.
42. Okuda Y, E Ogura, H Kondoh and Y Kamachi. (2010). B1 SOX coordinate cell specification with patterning and morphogenesis in the early zebrafish embryo. PLoS Genet 6:e1000936.
43. Trowe MO, L Zhao, AC Weiss, V Christoffels, DJ Epstein and A Kispert. (2013). Inhibition of Sox2-dependent activation of Shh in the ventral diencephalon by Tbx3 is required for formation of the neurohypophysis. Development 140:2299-2309.
44. Briggs JA, J Sun, J Shepherd, DA Ovchinnikov, TL Chung, SP Nayler, LP Kao, CA Morrow, NY Thakar, et al. (2013). Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology. Stem Cells 31:467-478.
45. Mines MA, CJ Yuskaitis, MK King, E Beurel and RS Jope. (2010). GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One 5:e9706.
46. Franklin AV, MK King, V Palomo, A Martinez, LL McMahon and RS Jope. (2014). Glycogen synthase kinase-3 inhibitors reverse deficits in long-Term potentiation and cognition in fragile X mice. Biol Psychiatry 75:198-206.
47. Chen T, JS Lu, Q Song, MG Liu, K Koga, G Descalzi, YQ Li and M Zhuo. (2014). Pharmacological rescue of cortical synaptic and network potentiation in a mouse model for fragile X syndrome. Neuropsychopharmacology 39:1955-1967.
48. Ring DB, KW Johnson, EJ Henriksen, JM Nuss, D Goff, TR Kinnick, ST Ma, JW Reeder, I Samuels, et al. (2003). Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52:588-595.
49. Huang SM, YM Mishina, S Liu, A Cheung, F Stegmeier, GA Michaud, O Charlat, E Wiellette, Y Zhang, et al. (2009). Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461:614-620.
50. Esfandiari F, A Fathi, H Gourabi, S Kiani, S Nemati and H Baharvand. (2012). Glycogen synthase kinase-3 inhibition promotes proliferation and neuronal differentiation of human-induced pluripotent stem cell-derived neural progenitors. Stem Cells Dev 21:3233-3243.
51. Ascano M, Jr., N Mukherjee, P Bandaru, JB Miller, JD Nusbaum, DL Corcoran, C Langlois, M Munschauer, S Dewell, et al. (2012). FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 492:382-386.
52. Bhakar AL, G Dolen and MF Bear. (2012). The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci 35:417-443.
53. Abitbol M, C Menini, AL Delezoide, T Rhyner, M Vekemans and J Mallet. (1993). Nucleus basalis magnocellularis and hippocampus are the major sites of FMR-1 expression in the human fetal brain. Nat Genet 4:147-153.
54. Bylund M, E Andersson, BG Novitch and J Muhr. (2003). Vertebrate neurogenesis is counteracted by Sox1-3 activity. Nat Neurosci 6:1162-1168.
55. Niu W, T Zang, DK Smith, TY Vue, Y Zou, R Bachoo, JE Johnson and CL Zhang. (2015). SOX2 reprograms resident astrocytes into neural progenitors in the adult brain. Stem Cell Reports 4:780-794.
56. Stolt CC and M Wegner. (2010). SoxE function in vertebrate nervous system development. Int J Biochem Cell Biol 42:437-440.
57. Kang P, HK Lee, SM Glasgow, M Finley, T Donti, ZB Gaber, BH Graham, AE Foster, BG Novitch, RM Gronostajski and B Deneen. (2012). Sox9 and NFIA coordinate a transcriptional regulatory cascade during the initiation of gliogenesis. Neuron 74:79-94.
58. Jiang T, CC Hou, ZY She and WX Yang. (2013). The SOX gene family: function and regulation in testis determination and male fertility maintenance. Mol Biol Rep 40:2187-2194.
59. Wuelling M and A Vortkamp. (2011). Chondrocyte proliferation and differentiation. Endocr Dev 21:1-11.
60. Ghahramani Seno MM, P Hu, FG Gwadry, D Pinto, CR Marshall, G Casallo and SW Scherer. (2011). Gene and miRNA expression profiles in autism spectrum disorders. Brain Res 1380:85-97.
61. Colak D, N Zaninovic, MS Cohen, Z Rosenwaks, WY Yang, J Gerhardt, MD Disney and SR Jaffrey. (2014). Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science 343:1002-1005.
62. Avitzour M, H Mor-Shaked, S Yanovsky-Dagan, S Aharoni, G Altarescu, P Renbaum, T Eldar-Geva, O Schonberger, E Levy-Lahad, S Epsztejn-Litman and R Eiges. (2014). FMR1 epigenetic silencing commonly occurs in undifferentiated fragile X-Affected embryonic stem cells. Stem Cell Reports 3:699-706.
63. Alisch RS, T Wang, P Chopra, J Visootsak, KN Conneely and ST Warren. (2013). Genome-wide analysis validates aberrant methylation in fragile X syndrome is specific to the FMR1 locus. BMC Med Genet 14:18.
64. de Esch CE, M Ghazvini, F Loos, N Schelling-Kazaryan, W Widagdo, ST Munshi, E van der Wal, H Douben, N Gunhanlar, et al. (2014). Epigenetic characterization of the FMR1 promoter in induced pluripotent stem cells from human fibroblasts carrying an unmethylated full mutation. Stem Cell Reports 3:548-555.
65. Bar-Nur O, I Caspi and N Benvenisty. (2012). Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives. J Mol Cell Biol 4:180-183.
66. Urbach A, O Bar-Nur, GQ Daley and N Benvenisty. (2010). Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 6:407-411.